QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Immunome, Inc. (IMNM)

Healthcare

No action
Fundamental
2
Sentiment
3
Technical
2

Do Nothing: fundamentalScore is 2, below the required floor of 3 — the strategy requires fundamentalScore ≥ 3 before any bullish entry, and the chart (2/5: price below SMA50/SMA200 with MACD -0.37 below zero) offers no tradable bullish setup either; qualitativeScore 3 passes but cannot rescue the fundamental floor.

Analysis as of 2026-11-13· more than 2 trading days ago

Company overview

Immunome, Inc. is a biotechnology company focused on developing oncology therapeutics, including antibody-drug conjugates. Its key clinical assets include Varegacestat, a gamma secretase inhibitor in Phase 3 trials, and IM-1021, an antibody-drug conjugate in Phase 1 trials.

Fundamental

weak
Fundamental2
Weak fundamentals

Immunome's financials are weak, with zero revenue, high cash burn, and reliance on a single FDA decision.

Pre-revenue clinical-stage biotech: a genuinely strong, debt-free balance sheet ($461.6 million of cash and marketable securities, runway into 2028) attached to an income statement with zero revenue, a ~$282 million trailing net loss, negative returns on equity and invested capital, accelerating cash burn, and a steadily rising share count. Value rests almost entirely on one binary FDA decision (varegacestat, PDUFA target date 28 April 2027) against an already-approved competitor, while the discounted-cash-flow models sit ~60% below the market price and analyst targets sit ~74% above it.

Sentiment

fair
Sentiment3
Mixed sentiment

Sentiment is mixed with conflicting catalysts and moderate red flags, including a supply overhang.

The near-term setup is a genuinely two-sided catalyst map: the 2026-10-30 EMA marketing-authorization validation for varegacestat and an announced ASH 2026 first-in-human IM-1021 data readout (meeting start 2026-12-05) sit against a bearish 2026-11-09 Q3 EPS miss (-$0.76 vs -$0.60 consensus), post-print analyst forecast cuts, and a 4.43M-share selling-stockholder resale plus S-3ASR mixed shelf that adds near-term supply. Media polarity in the scoring window is measured but flat (aggregate ≈ -0.03 on four scored items) while the baseline aggregate was unmeasurable after two extraction failures, so the delta is determinate at item level only (mild deterioration from a constructive Aug-Oct baseline, moderate confidence); no severe red flag fired, but two moderate flags fire (growth-context dilutive supply overhang and conflicting catalyst signals), so a moderate red-flag cap applies.

Technical

weak
Technical2
Downtrend persists

The stock is in a downtrend with no bullish technical setup, trading below key moving averages.

Chart score 2/5 (weak/mixed, bounce-only). Trend frame: price 18.69 sits just above the SMA20 (18.57) but below the EMA9 (18.82), EMA21 (18.98), SMA50 (20.65) and SMA200 (22.21), essentially at the 18.52 daily VWAP — a bounce inside a still-falling intermediate downtrend (shares are ~31% below the 27.25 September high, and the SMA50 sits below the SMA200). Momentum frame: RSI14 46.4 and Williams %R -74.5 are neutral-to-soft; the MACD line at -0.37 is still below zero but above its -0.57 signal, with the histogram positive (+0.19) throughout the 10-30 to 11-13 display window — repair, not trend; ADX14 24.1 and falling from 31.9 says the prior downtrend is losing force rather than a new uptrend taking over. Volatility frame: ATR14 1.24 = 6.63% of price; StdDev20 0.76 (4.1% of price). Volume frame: 20-day average dollar volume ~$27.9M with the last three completed sessions ~$18.3M / $13.7M / $21.7M of regular-session dollar volume — liquid and constructive. The last two weeks carved an 17.3-19.8 base on decent volume, but with price below the SMA50 and MACD below zero a pullback/oversold limit would also have been countertrend-blocked, and a breakout stop has no confirmed range expansion (most recent session range 0.66 vs 3xATR 3.72). Verdict: no tradable bullish setup, and the fundamental override (fundamentalScore 2 < 3) independently hard-blocks any long entry.

You’re looking at 2026-11-13 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.